United Kingdom · Question · Written question
UIN 150776
Coronavirus: Screening
Introduced
8 February 2021
Last action
8 March 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
8 March 2021
Summary
To ask the Secretary of State for Health and Social Care, on what basis (a) Omega Diagnostics, (b) SureScreen and (c) Global Access Diagnostics were chosen for contracts to produce lateral flow devices for covid-19.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
8 February 2021
Written question
To ask the Secretary of State for Health and Social Care, on what basis (a) Omega Diagnostics, (b) SureScreen and (c) Global Access Diagnostics were chosen for contracts to produce lateral flow devices for covid-19.
Source: Commons
8 March 2021
Answer
SureScreen, Global Access Diagnostics and Omega were selected via targeted engagement with the wider United Kingdom testing industry. This engagement was coordinated via the Rapid Antigen Consortium – an open forum bringing together UK companies with appl...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-02-08/150776
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1284921
- uk · wq-1284921 · source updated 8 March 2021